Sustainable Cell Therapeutics
Advanced cell therapy research for novel cancer treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| Total Funding | 000k | ||
ARC Therapies Inc., formerly known as Sustainable Cell Therapeutics, is a biotechnology company established in 2022 and headquartered in Tokyo, Japan. It originated as a certified startup from the National Cancer Center Japan. The company focuses on discovering and developing cancer therapeutics through an integrated approach that combines immunology, genetics, and metabolism, with a goal of achieving complete cancer cures.
ARC Therapies develops cell-based medicines and cancer immunotherapies, including chimeric antigen receptor (CAR)-T cells designed to attack tumors. A key area of their research involves the gut microbiome's role in cancer treatment. The company is advancing a newly identified gut microbe, designated ARC0812 (RUX), toward clinical application as a potential immune adjuvant in human cancer immunotherapy. This microbe was found to be prevalent in cancer patients who responded well to immune checkpoint inhibitors, and it activated anti-tumor immune responses in preclinical models. The company is preparing for preclinical and human clinical trials to assess its administration methods and therapeutic efficacy.
Financially, ARC Therapies has received investment from Healthcare Innovation and LINK-J. The company's former name is listed as Sustainable Cell Therapeutics.
Keywords: cancer immunotherapy, cell therapy, biotechnology, oncology, National Cancer Center Japan, immunology, genetics, metabolism, gut microbiome, immune adjuvant, CAR-T, cancer therapeutics, clinical trials, ARC0812, RUX, YB328